ATHA
No price yet
Announcements
Nothing here yet
Daily updates
Nothing here yet
FDA designations
Nothing here yet
News
- Athira licenses lasofoxifene Phase 3 program for metastatic breast cancer with $236M financingDec 18, 2025
- Athira Pharma presents Phase 1 trial results of ATH-1105 at ALS Nexus 2025Aug 14, 2025
- Athira Pharma to present data from first-in-human Phase 1 clinical trial of ATH-1105 at the 4th Annual ALS Drug Development Summit.May 13, 2025